Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

This study has been completed.
Information provided by (Responsible Party):
Morie Gertz, Mayo Clinic Identifier:
First received: March 15, 2012
Last updated: January 20, 2014
Last verified: January 2014
This study examines the value of stem cell transplantation in managing light chain amyloidisis.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Reporting of Amyloidosis Stem Cell Transplantation Outcomes

Resource links provided by NLM:

Further study details as provided by Morie Gertz, Mayo Clinic:

Primary Outcome Measures:
  • Survival [ Time Frame: up to 8 years ]

Enrollment: 400
Study Start Date: June 2011
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Detailed Description:
  1. How does age at diagnosis affect prognosis in primary amyloidosis?
  2. How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis?
  3. How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis?
  4. How does initial treatment affect prognosis in primary amyloidosis?

4. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient receiving transplantation

Inclusion Criteria:

  • Eligible for Stem cell transplantation less than age 75

Exclusion Criteria:

  • Creatinine > 3.0
  • BNP > 10000
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01606280

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
  More Information

Responsible Party: Morie Gertz, principal investigator, Mayo Clinic Identifier: NCT01606280     History of Changes
Other Study ID Numbers: 11-005003
Study First Received: March 15, 2012
Last Updated: January 20, 2014

Keywords provided by Morie Gertz, Mayo Clinic:

Additional relevant MeSH terms:
Proteostasis Deficiencies
Metabolic Diseases processed this record on May 25, 2017